Biologic therapies for severe pediatric asthma: efficacy, safety, and biomarker-guided selection
Biologic therapies have reshaped the care of severe pediatric asthma, operationalizing precision medicine through immunologic endotyping and biomarker-guided selection. Priorities now include standardized definitions of response and remission, robust long-term safety data, and strategies to ensure equitable access across diverse pediatric populations.
Authors
- Enrico Tondina (ORCID: https://orcid.org/0000-0001-9962-2608)
- Alessia Claudia Codazzi (ORCID: https://orcid.org/0000-0003-3329-0879)
- C Dutto
- Ilaria Brambilla (ORCID: https://orcid.org/0000-0002-9870-414X)
- R Castorina
- Giovanni Lepore
- Rossana Di Micco
- Livia Leoncini Bartoli
Institutions
- University of Pavia (IT)
- Policlinico San Matteo Fondazione (IT)
Publication Details
- Journal
- Frontiers in Allergy
- Published
- 2026-01-20
- DOI
- https://doi.org/10.3389/falgy.2026.1757445
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00